Ms. Nisa Leung
Nisa Leung is a Managing Partner of Qiming Venture Partners and leading its health care investments. Qiming Venture Partners is a leading investment firm in China which currently manages funds with over USD 3 billion in assets and investment in 230 companies.
Nisa was named Venture Capital Professional of the Year by Asian Venture Capital Journal in 2017. She currently sits on the board of Gan & Lee Pharmaceutical, Zai Lab (NASDAQ: ZLAB), Nurotron, Venus MedTech, Goodwill Information Technology, dMed, LIH Rehabilitation, CanSino Biotechnology and Berry Genomics (SZSE:000710). Her other investments include Acea Biosciences, Aeonmed Medical, Alltech Medical, CITIC Pharmaceuticals (acquired by Shanghai Pharmaceutical HKSE: 02607), Crown Bioscience (GTSM: 6554), Origene Technologies (acquired by VCAN Bio SHSE: 600645), Richen, VR Medical, Wuxi Leiming, Chain Medical Labs, Suzhou Qiagen and New Horizon Bio.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is currently visiting lecturer at Harvard Law School, a founding member and Vice Chair of PhIRDA (China Pharmaceutical Innovation and Research Development Association) Investment Committee, member of Committee on Hong Kong Innovation and Technology (I&T) Development and Re-Industrialization, convener of Venture Investors Alliance of Hong Kong, director of Young Entrepreneur Development Council, , council member of HKUST Business School, , member of Task Force on Review of Research Policy & Funding of University Grants Committee and serves on the Board of Governors of the Hotchkiss School.